Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases
Yasuhiko Izumi, Yutaka Koyama, Jorge Ghiso, Agueda A Rostagno · 2024
Read Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases by Yasuhiko Izumi, Yutaka Koyama, Jorge Ghiso, Agueda A Rostagno (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11727036.txt.
Description
Izumi and Koyama review dimethyl fumarate, a drug first used for psoriasis and later for multiple sclerosis, and ask how much of its calming effect on inflammation runs outside its best-known pathway. The drug switches on the Nrf2 pathway, which defends cells against oxidative stress, a driver of brain diseases.
Recent work shows the drug also calms inflammation without Nrf2. As an electrophilic compound, it bonds to cysteine sites on proteins and changes how they work, which can help or cause side effects. The authors argue for a chemical proteomics approach: find and modify only the cysteine sites that give the benefit. That strategy could yield safer drugs for diseases where the brain slowly breaks down.
Catalog record
| CREATOR | Yasuhiko Izumi, Yutaka Koyama, Jorge Ghiso, Agueda A Rostagno |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |